WEBULL
WebtradeDownload

Is H. Lundbeck (CPSE:HLUN B) Undervalued After New Bexicaserin Data Took Center Stage?

Simply Wall St · 2d ago

H. Lundbeck (CPSE:HLUN B) has put its epilepsy pipeline in focus after announcing that new mechanistic and clinical data for bexicaserin will be featured at the European Epilepsy Congress in Athens this month.

For context, H. Lundbeck shares now trade at DKK44.16, with a 30-day share price return of 6.46% and a year-to-date share price return of 2.70%. The 1-year total shareholder return of 6.10% and 3-year total shareholder return of 32.50% suggest momentum has been building over a longer stretch as the pipeline story, including bexicaserin, has come into sharper focus.

Spot emerging epilepsy and neurology opportunities by scanning hand-picked peers to H. Lundbeck in our list of solid balance sheet and fundamentals (193 results).

The recent climb in H. Lundbeck’s share price could be read as a quick sentiment reset around bexicaserin, or as a measured response to the broader pipeline and earnings profile. Which explanation fits the current valuation?

Most Popular Narrative: 9.4% Undervalued

Analysts following H. Lundbeck see fair value at DKK48.73 versus the last close at DKK44.16. This frames the recent bexicaserin news against an already supportive narrative built on the broader neuroscience portfolio and capital allocation plan.

A maturing pipeline with 5-6 mid

to late-stage assets (bexicaserin, amlenetug, D1/D2 agonist) targeting high unmet needs in CNS and neuro-rare diseases, underpins prospects for portfolio diversification and long-term growth, likely driving both revenue and gross margin expansion as late-stage candidates move towards approval.

Read the complete narrative.

Want to see what sits behind that pipeline story and the DKK48.73 fair value tag? The key ingredients are top line expectations, margin shaping, and the earnings multiple analysts think H. Lundbeck can support.

Result: Fair Value of DKK48.73 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the H. Lundbeck narrative can be knocked off course if key late stage CNS trials stumble or if generic competition erodes cash flows faster than expected.

Find out about the key risks to this H. Lundbeck narrative.

Next Steps

Unsure about the tone of this H. Lundbeck story so far? Act quickly, review the underlying data, and consider both the potential upside and the risks in 3 key rewards and 1 important warning sign.

Looking for more H. Lundbeck investment ideas?

If the H. Lundbeck setup interests you, do not stop here. Broaden your watchlist with other focused opportunities uncovered by the Simply Wall Street Screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.